Trust Co. of Vermont Has $747,000 Position in Prestige Consumer Healthcare Inc. (NYSE:PBH)

Trust Co. of Vermont trimmed its position in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) by 3.6% during the fourth quarter, HoldingsChannel.com reports. The firm owned 9,564 shares of the company’s stock after selling 362 shares during the period. Trust Co. of Vermont’s holdings in Prestige Consumer Healthcare were worth $747,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Quest Partners LLC boosted its position in Prestige Consumer Healthcare by 2,826.7% during the 2nd quarter. Quest Partners LLC now owns 439 shares of the company’s stock worth $30,000 after buying an additional 424 shares during the period. Envestnet Asset Management Inc. lifted its holdings in shares of Prestige Consumer Healthcare by 14.9% during the second quarter. Envestnet Asset Management Inc. now owns 67,814 shares of the company’s stock worth $4,669,000 after purchasing an additional 8,782 shares during the period. Mercer Global Advisors Inc. ADV grew its stake in shares of Prestige Consumer Healthcare by 6.7% in the second quarter. Mercer Global Advisors Inc. ADV now owns 5,969 shares of the company’s stock worth $411,000 after purchasing an additional 374 shares during the last quarter. Blair William & Co. IL increased its holdings in Prestige Consumer Healthcare by 4.4% in the second quarter. Blair William & Co. IL now owns 84,477 shares of the company’s stock valued at $5,816,000 after purchasing an additional 3,594 shares during the period. Finally, Canada Pension Plan Investment Board bought a new position in Prestige Consumer Healthcare during the 2nd quarter worth $151,000. 99.95% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on PBH shares. StockNews.com lowered Prestige Consumer Healthcare from a “buy” rating to a “hold” rating in a research report on Thursday. Jefferies Financial Group reissued a “hold” rating and set a $76.00 target price (up previously from $70.00) on shares of Prestige Consumer Healthcare in a research report on Tuesday, September 24th. Sidoti lowered shares of Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 price target for the company. in a report on Monday, December 9th. DA Davidson reaffirmed a “buy” rating and issued a $95.00 price objective on shares of Prestige Consumer Healthcare in a research note on Monday, November 11th. Finally, Raymond James raised shares of Prestige Consumer Healthcare to a “moderate buy” rating in a research note on Thursday, December 19th. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $85.25.

Insider Activity at Prestige Consumer Healthcare

In related news, CEO Ronald M. Lombardi sold 10,875 shares of the stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $82.60, for a total value of $898,275.00. Following the transaction, the chief executive officer now directly owns 320,952 shares in the company, valued at $26,510,635.20. This trade represents a 3.28 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider William P’pool sold 8,987 shares of the business’s stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $81.85, for a total transaction of $735,585.95. Following the sale, the insider now owns 20,058 shares of the company’s stock, valued at $1,641,747.30. This trade represents a 30.94 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 38,810 shares of company stock valued at $3,187,300 in the last three months. Corporate insiders own 1.60% of the company’s stock.

Prestige Consumer Healthcare Price Performance

Prestige Consumer Healthcare stock opened at $78.58 on Friday. The stock has a market capitalization of $3.88 billion, a price-to-earnings ratio of 19.12, a PEG ratio of 2.08 and a beta of 0.51. Prestige Consumer Healthcare Inc. has a 52-week low of $58.22 and a 52-week high of $86.36. The company has a debt-to-equity ratio of 0.61, a quick ratio of 2.10 and a current ratio of 3.56. The stock’s 50 day moving average price is $80.52 and its two-hundred day moving average price is $74.53.

Prestige Consumer Healthcare (NYSE:PBH) last issued its earnings results on Thursday, November 7th. The company reported $1.09 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.09. Prestige Consumer Healthcare had a net margin of 18.54% and a return on equity of 12.23%. The business had revenue of $283.79 million for the quarter, compared to analyst estimates of $282.09 million. During the same period in the prior year, the firm earned $1.07 earnings per share. Prestige Consumer Healthcare’s revenue was down .9% on a year-over-year basis. On average, equities analysts predict that Prestige Consumer Healthcare Inc. will post 4.44 earnings per share for the current year.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.